soul trial oral semaglutide cardiovascular outcomes 2024 2025 Updates in Medicine on X: "SOUL (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in SOUL: Oral Semaglutide Cuts CV

The mechanical unloading of joints and reduction in systemic inflammation associated with weight loss may account for the observed improvements

Personalization Through Genetic Testing for Optimal Results PlexusDx's Precision Peptide Genetic Test analyzes your genetic variants in 14 metabolic pathways across 49 peptides, identifying genetic predictors of GLP-1 receptor function, appetite regulation, and weight loss potential

Scientists quickly refocused their research efforts in large multidisciplinary collaborations and made tremendous progress in a short space of time [7]

Chan School of Public Health , Apr

And, in true Shiseido form, this is a skincare-forward foundation that highlights ingredients like probiotics and niacinamide to hydrate the skin barrier

Cooled in salads: Cooling cooked black beans increases their resistant starch, which may boost gut health benefits